Market Intelligence & Recommendations
AI-powered insights on emerging opportunities and watchlist updates
High-Priority Allocation Opportunity
Catalyst Ventures III (Sarah Chen) is accepting final allocations for Q3 close. Emerging manager Sarah Chen turned $15M initial fund into $340M in realized returns with only $8M of outside capital. 3-year alpha of +890bps vs biotech indices with 73% clinical trial success rate vs 15% industry average. Limited capacity remaining: ~$25M for qualified LPs.
Request AllocationFocus Therapeutics - Market Entry
Focus Therapeutics is launching their second fund targeting $500M, focusing on precision oncology. Recent FDA breakthrough designation for lead portfolio company creates 18-month performance tailwind. First close scheduled for September 2025.
Add to WatchlistPrestige Ventures - Due Diligence Required
Despite blue-chip profile and $2.3B in recent fundraising, Prestige Ventures has delivered sub-benchmark returns for 3 consecutive vintage years. Completely missed the AI boom (0% allocation vs 23% sector average). Outsized unrealized returns driven by exposure to overvalued early-stage names. Fund is actively fundraising for a $3B+ follow-on with significant allocation risk.
View AnalysisBiotech Investment Manager Directory
Comprehensive performance metrics and risk-adjusted analysis
| Fund / Manager | Strategy | AUM / Vintage | Portfolio | Net IRR | Alpha | Sharpe | Max DD | Biotech Metrics | Performance Attribution | Grade | Action |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Catalyst Ventures III ↗
Sarah Chen, MD/PhD
|
VC Growth |
$340M
2022
|
23 companies
6 exits
|
47.2% | +890bps | 1.84 | -12.3% |
Trial Success: 73%
IPOs: 2 | M&A: 4 Avg Exit: 4.2yr |
67% clinical catalysts
23% M&A timing 10% sector allocation |
A | |
|
BioCapital Partners IV
Michael Rodriguez
|
Hedge Fund |
$1.2B
2021
|
45 positions
12 exits
|
23.1% | +340bps | 1.52 | -18.7% |
Trial Success: 45%
IPOs: 3 | M&A: 9 Avg Exit: 2.8yr |
43% stock selection
31% market timing 26% sector rotation |
B+ | |
|
Focus Therapeutics Fund
Dr. Lisa Park
|
Long-Only |
$750M
2020
|
18 companies
8 exits
|
31.8% | +520bps | 1.67 | -15.2% |
Trial Success: 67%
IPOs: 3 | M&A: 5 Avg Exit: 3.5yr |
78% precision medicine
15% regulatory timing 7% market conditions |
A- | |
|
Prestige Ventures V ↗
James Wellington III
|
VC Growth |
$2.3B
2023
|
67 companies
8 exits
|
8.3% | -280bps | 0.94 | -34.2% |
Trial Success: 28%
IPOs: 1 | M&A: 7 Avg Exit: 5.8yr |
45% momentum trades
35% early-stage beta 20% size premium |
D+ | |
|
Genomic Partners II
Dr. Amy Zhang
|
VC Early |
$425M
2022
|
31 companies
4 exits
|
28.7% | +450bps | 1.45 | -21.5% |
Trial Success: 58%
IPOs: 1 | M&A: 3 Avg Exit: 4.1yr |
82% gene therapy
12% platform tech 6% regulatory arb |
B+ | |
|
Quantum Bio Fund
Robert Kim, PhD
|
Hedge Fund |
$680M
2021
|
38 positions
15 exits
|
19.4% | +180bps | 1.28 | -16.8% |
Trial Success: 41%
IPOs: 4 | M&A: 11 Avg Exit: 2.2yr |
52% AI/ML platforms
28% biomarker plays 20% data analytics |
B | |
|
Rare Disease Capital
Dr. Maria Santos
|
VC Growth |
$290M
2023
|
14 companies
2 exits
|
42.1% | +720bps | 1.91 | -9.8% |
Trial Success: 86%
IPOs: 1 | M&A: 1 Avg Exit: 3.8yr |
91% orphan drug premium
6% regulatory fast-track 3% market timing |
A+ | |
|
Nexus Biotech Fund
David Thompson
|
Long-Only |
$950M
2020
|
28 companies
11 exits
|
16.8% | +120bps | 1.15 | -22.4% |
Trial Success: 39%
IPOs: 3 | M&A: 8 Avg Exit: 4.5yr |
48% large-cap selection
32% sector rotation 20% dividend yield |
C+ |
Manager Deep Dive
Comprehensive analysis and portfolio insights